invertbio.com

What It Is

Invert is an infrastructure and intelligence platform for bioprocessing. Its core goal is to connect equipment, instruments, ELNs, analytical results, and batch information across process development and manufacturing, turning them into traceable, searchable data assets that can be used for analysis and reporting. It is clearly not a general-purpose BI tool; instead, it focuses on biopharma upstream and downstream processes, CMC, MSAT, and regulated manufacturing environments.

Core Features and Integrations

Based on the collected information, Invert is built on its Foundation data layer: it unifies instrument, historian, and process data across different scales, offering a centralized batch database, parameter standardization, timestamp alignment, data lineage, and cross-scale comparison. The Enablement layer focuses on deviation investigations, root cause analysis, and insights across unit operations. Intelligence and Invert Assist are used for AI-generated process characterization reports, activity summaries, statistical analysis, and trend charts. On the integration side, the materials explicitly mention bioreactor exports, offline sample logs, HPLC, osmometry, ELN metadata, and OPC-UA/OPC-DA edge data collection for on-site equipment.

Pricing, Access Control, and Compliance

The official website only shows a Pricing entry point and Book a demo, with no public disclosure of plans, prices, a free tier, or trial information. It is likely oriented toward enterprise sales and project-based implementation. For access control, Invert uses Auth0 and supports enterprise SSO, RBAC, and organization-level access control. Its compliance disclosures are relatively complete: SOC 2 Type II, ISO 27001, support for FDA 21 CFR Part 11 and GDPR, as well as references to EU GMP Annex 11, audit trails, AES-256 encryption at rest, TLS encryption in transit, tenant isolation, single-tenant deployment options, and AWS Bedrock AI security controls.

Pros, Cons, and Who It’s For

The main strengths are its strong industry fit and its ability to reduce the burden of manual spreadsheet work, cross-batch comparisons, and report generation. Official case studies indicate that it can significantly reduce the time required for data preparation and deviation investigations. The drawbacks are its opaque pricing, the need to evaluate implementation complexity, data migration costs, and compatibility with existing validated systems on a case-by-case basis, as well as the lack of public API/SDK details. It is better suited to large biopharma companies, CDMOs, CMC development teams, and MSAT teams, rather than companies that only need general project management or standard data dashboards.

Access from China and Alternatives

The collected text does not provide information on access from mainland China, Chinese-language support, RMB payments, or local deployment policies, so china_access can only be considered unknown. For deployment in Chinese pharmaceutical companies, key points to verify include network connectivity, cross-border data transfer, AWS regions, compliance audits, and payment/contract arrangements. Alternatives to compare include AVEVA PI, Benchling, TetraScience, Sapio Sciences, as well as domestic laboratory informatics, LIMS/ELN, and biomanufacturing data platforms.